| Gastro-enteropancreatic neuroendocrine tumor
Lutathera vs Somatuline Depot
Side-by-side clinical, coverage, and cost comparison for gastro-enteropancreatic neuroendocrine tumor.Deep comparison between: Lutathera vs Somatuline Depot with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsSomatuline Depot has a higher rate of injection site reactions vs Lutathera based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Somatuline Depot but not Lutathera, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Lutathera
Somatuline Depot
At A Glance
IV infusion
Every 8 weeks
Radiolabeled somatostatin analog
SC injection
Every 4 weeks
Somatostatin analog
Indications
- Gastro-enteropancreatic neuroendocrine tumor
- Acromegaly
- Gastro-enteropancreatic neuroendocrine tumor
- Malignant Carcinoid Syndrome
Dosing
Gastro-enteropancreatic neuroendocrine tumor 7.4 GBq (200 mCi) IV every 8 weeks (+/- 1 week) for a total of 4 doses in adults and pediatric patients 12 years and older.
Acromegaly 90 mg deep SC injection every 4 weeks for 3 months; adjust thereafter to 60-120 mg every 4 weeks based on GH and/or IGF-1 levels; controlled patients may extend to 120 mg every 6 or 8 weeks. Starting dose reduced to 60 mg every 4 weeks in moderate or severe renal or hepatic impairment.
Gastro-enteropancreatic neuroendocrine tumor, Malignant Carcinoid Syndrome 120 mg deep SC injection every 4 weeks; if already receiving treatment for GEP-NET, do not administer an additional dose for carcinoid syndrome.
Contraindications
—
- History of hypersensitivity to lanreotide (including angioedema and anaphylaxis)
Adverse Reactions
Most common Nausea, vomiting, lymphopenia, anemia, fatigue, creatinine increased, hyperglycemia, GGT increased, leukopenia, thrombocytopenia
Serious Myelodysplastic syndrome, acute leukemia, renal failure, cardiac failure, myocardial infarction, neuroendocrine hormonal crisis
Postmarketing Hypersensitivity reactions including angioedema
Most common (>5%) Diarrhea, abdominal pain, nausea, constipation, flatulence, vomiting, loose stools, cholelithiasis, injection site reactions, musculoskeletal pain, arthralgia, headache, hyperglycemia, hypertension, dizziness
Serious Cholelithiasis and complications of cholelithiasis, hyperglycemia and hypoglycemia, cardiovascular abnormalities, thyroid function abnormalities, steatorrhea and malabsorption of dietary fats
Postmarketing Pancreatic exocrine insufficiency, steatorrhea, cholecystitis, cholangitis, pancreatitis, angioedema, anaphylaxis, injection site abscess
Pharmacology
Lutetium Lu 177 dotatate is a radiolabeled somatostatin analog that binds somatostatin receptors with highest affinity for SSTR2; upon internalization into receptor-positive tumor cells, beta-minus emission from lutetium-177 induces cellular damage via free radical formation in target and neighboring cells.
Lanreotide is a synthetic octapeptide analog of natural somatostatin with high binding affinity for somatostatin receptors SSTR2 and SSTR5; it inhibits growth hormone and IGF-1 secretion, reduces carcinoid syndrome mediators (urinary 5-HIAA), and suppresses various endocrine, neuroendocrine, exocrine, and paracrine functions.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Lutathera
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
Somatuline Depot
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (9/12)
UnitedHealthcare
Lutathera
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Somatuline Depot
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Lutathera
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Somatuline Depot
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (2/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Neuroendocrine Tumors: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: Acromegaly: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
LutatheraView full Lutathera profile
Somatuline DepotView full Somatuline Depot profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.